4ff81b7f-2dbc-453f-a68b-fe40315b2ef7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.700
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- COMPLEMENT+0.400
- IL2_STAT5_SIGNALING+0.400
- APOPTOSIS+0.300
- E2F_TARGETS+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- GLYCOLYSIS-0.300
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ADIPOGENESIS-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- FATTY_ACID_METABOLISM-0.200
- NOTCH_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10842366 | — | — | 0.916 |
| 2 | MNG943 | — | — | 0.879 |
| 3 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.868 |
| 4 | R252 | — | — | 0.862 |
| 5 | C3N-00247 | — | cohortMD2 | 0.861 |
| 6 | 8914dcad-b703-4099-a5dd-edb9cedc104c | — | — | 0.848 |
| 7 | 5a674268-79a8-4a30-a6db-a4fd0b83e208 | — | — | 0.848 |
| 8 | s0112287 | — | — | 0.844 |
| 9 | s0122149 | — | — | 0.842 |
| 10 | C3L-03961 | — | cohortSQ1 | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.700 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |